Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization

DSpace/Manakin Repository

Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization

Citable link to this page


Title: Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization
Author: Cheng, Sheng-Fu; Dastjerdi, Mohammad H.; Ferrari, Giulio; Okanobo, Andre; Bower, Kraig S.; Ryan, Denise S.; Amparo, Francisco; Stevenson, William; Hamrah, Pedram; Nallasamy, Nambi; Dana, Reza

Note: Order does not necessarily reflect citation order of authors.

Citation: Cheng, Sheng-Fu, Mohammad H. Dastjerdi, Giulio Ferrari, Andre Okanobo, Kraig S. Bower, Denise S. Ryan, Francisco Amparo, et al. 2012. “Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization.” American Journal of Ophthalmology 154 (6) (December): 940–948.e1. doi:10.1016/j.ajo.2012.06.007.
Full Text & Related Files:
Abstract: Purpose

To evaluate the safety and efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV).


Prospective, non-randomized, interventional case series.



Institutional, multicenter clinical trial.

Study Population

Twenty eyes from 20 patients with stable corneal NV.

Intervention Procedures

Patients were treated with topical 1.0% for 3 weeks and monitored for a total of 24 weeks.

Main Outcome Measures

Primary outcome measures included: neovascular area, defined as the area of the corneal vessels themselves; vessel caliber, defined as the mean corneal vessel diameter; and invasion area, defined as the fraction of the total cornea into which the vessels extended. The occurrence of ocular and systemic adverse events was closely monitored.


As compared to the baseline visit, patients exhibited a statistically significant improvement in neovascular area by week 6 (P = .007) and vessel caliber by week 12 (P = .006). At the final visit, neovascular area, vessel caliber, and invasion area were reduced by 47.5%, 36.2%, and 20%, respectively. The decreases in neovascular area and vessel caliber were statistically significant (P < .001 and P = .003, respectively); however, the reduction in invasion area did not reach statistical significance (P = .06). There were no significant changes in the secondary outcomes and there were no adverse events.


Short-term topical bevacizumab treatment reduced the extent of stable corneal NV as measured by neovascular area and vessel caliber with no associated adverse events. Interestingly, the degree of treatment efficacy was inversely proportional to the baseline invasion area.
Published Version: 10.1016/j.ajo.2012.06.007
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search